GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer

This study aimed to investigate the association of the gene polymorphism with the outcomes and toxicities of treatments in breast cancer. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for the association of polymorphism with tumour response and toxicities, and the hazard r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2017-09, Vol.8 (42), p.72939-72949
Hauptverfasser: Ma, Jie, Zhu, Shao-Liang, Liu, Yang, Huang, Xiang-Yang, Su, Dan-Ke
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study aimed to investigate the association of the gene polymorphism with the outcomes and toxicities of treatments in breast cancer. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for the association of polymorphism with tumour response and toxicities, and the hazard ratios (HRs) and 95% CIs were calculated for the association between polymorphism and overall survival (OS). The statistical analysis showed that the polymorphism was not associated with tumour response or OS. A significant increase in the incidence of toxicities was observed (GA . AA OR = 1.45, 95% CI = 1.04-2.01, = 0.028; GG . AA OR = 1.47, 95% CI = 1.03-2.10, = 0.036; recessive model OR = 1.54, 95% CI = 1.13-2.09, = 0.006; and allele model OR = 1.35, 95% CI = 1.07-1.71, = 0.011), especially in the chemotherapy ± surgery group (GA . AA OR = 1.64, 95% CI = 1.05-2.56, = 0.030; recessive model OR = 1.72, 95% CI = 1.17-2.54, = 0.006; and allele model OR = 1.57, 95% CI = 1.11-2.21, = 0.010). Our results indicate that the polymorphism may be associated with increased toxicity, especially in patients treated with chemotherapy ± surgery.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.18513